Sutro Biopharma Q1 EPS Estimate Boosted by HC Wainwright

Sutro Biopharma, Inc. (NASDAQ:STRO) – Analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Sutro Biopharma in a research note issued on Monday, March 17th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.38) per share for the quarter, up from their prior estimate of ($0.82). HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.68) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.09) EPS.

Several other equities research analysts also recently weighed in on STRO. Citizens Jmp downgraded Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday, March 14th. Wedbush downgraded Sutro Biopharma from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $8.00 to $2.00 in a report on Friday, March 14th. Bank of America downgraded Sutro Biopharma from a “buy” rating to an “underperform” rating and reduced their price target for the company from $11.00 to $1.00 in a report on Friday, March 14th. JMP Securities reissued a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a report on Wednesday, December 11th. Finally, Piper Sandler set a $2.00 price target on Sutro Biopharma in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.63.

Sutro Biopharma Price Performance

Shares of NASDAQ STRO opened at $0.80 on Wednesday. Sutro Biopharma has a 1-year low of $0.76 and a 1-year high of $6.13. The business has a 50-day moving average of $1.66 and a 200-day moving average of $2.65. The company has a market capitalization of $65.64 million, a price-to-earnings ratio of -0.49 and a beta of 1.22.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($2.10). Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The company had revenue of $14.00 million during the quarter, compared to analysts’ expectations of $10.44 million. During the same period in the previous year, the company earned ($1.78) EPS.

Institutional Trading of Sutro Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of STRO. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Sutro Biopharma during the 4th quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. bought a new position in Sutro Biopharma in the 4th quarter worth approximately $32,000. Vontobel Holding Ltd. grew its holdings in Sutro Biopharma by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $46,000 after buying an additional 10,000 shares in the last quarter. ProShare Advisors LLC grew its holdings in Sutro Biopharma by 74.3% in the 4th quarter. ProShare Advisors LLC now owns 26,961 shares of the company’s stock worth $50,000 after buying an additional 11,494 shares in the last quarter. Finally, Velan Capital Investment Management LP bought a new position in Sutro Biopharma in the 4th quarter worth approximately $55,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.